- Home
- VCIC vs MRVI Comparison
VCIC vs MRVI Comparison
Compare VCIC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIC
- MRVI
- Stock Information
- Founded
- VCIC 2024
- MRVI 2014
- Country
- VCIC United States
- MRVI United States
- Employees
- VCIC N/A
- MRVI N/A
- Industry
- VCIC
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- VCIC
- MRVI Health Care
- Exchange
- VCIC NYSE
- MRVI Nasdaq
- Market Cap
- VCIC 304.0M
- MRVI 312.4M
- IPO Year
- VCIC 2024
- MRVI 2020
- Fundamental
- Price
- VCIC $10.41
- MRVI $2.69
- Analyst Decision
- VCIC
- MRVI Hold
- Analyst Count
- VCIC 0
- MRVI 10
- Target Price
- VCIC N/A
- MRVI $6.84
- AVG Volume (30 Days)
- VCIC 12.5K
- MRVI 1.9M
- Earning Date
- VCIC 01-01-0001
- MRVI 08-06-2025
- Dividend Yield
- VCIC N/A
- MRVI N/A
- EPS Growth
- VCIC N/A
- MRVI N/A
- EPS
- VCIC N/A
- MRVI N/A
- Revenue
- VCIC N/A
- MRVI $241,856,000.00
- Revenue This Year
- VCIC N/A
- MRVI N/A
- Revenue Next Year
- VCIC N/A
- MRVI $10.91
- P/E Ratio
- VCIC $78.14
- MRVI N/A
- Revenue Growth
- VCIC N/A
- MRVI N/A
- 52 Week Low
- VCIC $9.96
- MRVI $1.67
- 52 Week High
- VCIC $10.74
- MRVI $10.03
- Technical
- Relative Strength Index (RSI)
- VCIC N/A
- MRVI 58.67
- Support Level
- VCIC N/A
- MRVI $2.35
- Resistance Level
- VCIC N/A
- MRVI $2.93
- Average True Range (ATR)
- VCIC 0.00
- MRVI 0.17
- MACD
- VCIC 0.00
- MRVI -0.01
- Stochastic Oscillator
- VCIC 0.00
- MRVI 58.97
About VCIC VINE HILL CAP INVT CORP
Vine Hill Capital Investment Corp is a blank check company.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.